Table 1.
Characteristics of the patients
| Variables | Group A (n=43) | Group B (n=42) |
|---|---|---|
| Men | 32 (74.4) | 31 (73.8) |
| Age at entry (yr) | 7.0±4.3 | 7.1±3.7 |
| 1–5 | 25 (59.5) | 19 (45.2) |
| 6–10 | 8 (19.1) | 14 (33.3) |
| 11–13 | 6 (14.3) | 5 (11.9) |
| 14–18 | 4 (9.3) | 4 (9.5) |
| Minimal change subtype of NS | 43 (100.0) | 42 (100.0) |
| Duration of NS (mo) | 18.9±35.5 | 12.7±15.9 |
| History of SDNS | 26 (60.5) | 26 (61.9) |
| Previous treatment with immunosuppressive agent(s) | 8 (18.6) | 10 (23.8) |
| Mizoribine | 6 (14.0) | 9 (21.4) |
| Cyclophosphamide | 1 (2.3) | 1 (2.4) |
| Chlorambucil | 1 (2.3) | 0 (0) |
| Total protein (g/dl) | 5.9±0.6 | 5.8±0.7 |
| Albumin (g/dl) | 3.4±0.7 | 3.3±0.7 |
| BUN (mg/dl) | 11.5±4.0 | 12.8±3.4 |
| Creatinine (mg/dl) | 0.3±0.1 | 0.4±0.1 |
| Study baseline eGFR (ml/min per 1.73 m2) | 122.3±30.6 | 116.5±21.4 |
Values are n (%) or mean±SD. NS, nephrotic syndrome; SDNS, steroid-dependent nephrotic syndrome; eGFR, estimated GFR.